Ovarian tumors and genetic predisposition

Czech version

Authors: J. Štellmachová ; P. Vrtěl ; R. Vrtěl ; M. Janíková ; K. Kolaříková ; Martin Procházka ; R. Vodička
Authors‘ workplace: Ústav lékařské genetiky, FN Olomouc
Published in: Ceska Gynekol 2022; 87(3): 211-216
Category: Review Article
doi: https://doi.org/10.48095/cccg2022211

Overview

Objective: Summary of knowledge in the field of ovarian cancer and genetic predisposition. Results: Ovarian tumors are usually diagnosed at advanced stages of the disease and the prognosis for these patients is generally poor. The 5-year overall survival rate, regardless of the histopathological type of tumor, is around 44%. Germline mutations causing hereditary tumor syndromes are predominantly involved in the development of epithelial ovarian tumors. The most common is hereditary breast and ovarian cancer syndrome, which is caused by germline mutations in the tumor suppressor genes BRCA1 and BRCA2. Several other tumor suppressor genes and oncogenes are known to be associated with ovarian tumors and cause other types of tumor syndromes. Inherited tumor syndromes include Lynch syndrome, Peutz-Jegers syndrome, Gorlin syndrome, Li-Fraumeni syndrome and others. The indication for genetic examination of germline mutations is given by a clinical geneticist on the basis of the recommendation of the attending physician. At present, every ovarian tumor, primary peritoneal tumor and tube tumor diagnosed at any age is indicated for genetic testing. Conclusion: Early identification of genes for hereditary cancer syndromes, thanks to rapidly developing molecular genetic methods, is an important step towards personalized treatment of ovarian cancer and preventive measures in families at risk. It is also important to note that a negative molecular genetic test result does not exclude genetic risk.

Keywords:

prevention – ovarian cancer – germinal variant – hereditary tumor syndrome – molecular-genetic examination – familial mutations – genetic risks

Sources

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359–E386. doi: 10.1002/ ijc.29210.

2. Toss A, Tomasello C, Razzaboni E et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 2015; 2015: 341723. doi: 10.1155/ 2015/ 341723.

3. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev 2001; 10(2): 125–129. doi: 10.1097/ 00008469- 200104000-00002.

4. Feckaninová B, Pilka R, Slobodová Z. Recidiva vzácného maligního Brennerova tumoru ovaria. Ceska Gynekol 2021; 86(4): 250–257. doi: 10.48095/ cccg20211250.

5. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita. 2005 [online]. Available from: http:/ / www.svod.cz.

6. Walsh T, Casadei S, Lee MK et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011; 108(44): 18032–18037. doi: 10.1073/ pnas.1115052108.

7. Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction. Best Pract Res Clin Obstet Gynaecol 2017; 41: 31–48. doi: 10.1016/ j. bpobgyn.2016.10.017.

8. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005; 7(2): 60.

9. Jayson GC, Kohn EC, Kitchener HC et al. Ovarian cancer. Lancet 2014; 384(9951): 1376–1388. doi: 10.1016/ S0140-6736(13)621 46-7.

10. The American Cancer Society medical and editorial content team. Ovarian Cancer Risk Factors. 2022 [online]. Available from: https:/ / www. cancer.org/ cancer/ ovarian-cancer/ causes-risksprevention/ risk-factors.html.

11. Stewart LM, Holman CD, Finn JC et al. In vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynecol Oncol 2013; 129(2): 372–376. doi: 10.1016/ j.ygyno.2013.01.027.

12. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012; 124(1): 164–169. doi: 10.1016/ j.ybyno.2011.10.001.

13. Chittenden BG, Fullerton G, Maheshwari A et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19(3): 398–405. doi: 10.1016/ s1472-6483(10)60175-7.

14. National Institute of Child Health and Human Development. How many people are affected or at risk for PCOS? 2013 [online]. Available from: https:/ / web.archive.org/ web/ 20150304124420/ http:/ www.nichd.nih.gov/health/ topics/ PCOS/ conditioninfo/ Pages/ risk. aspx.

15. Goodman NF, Cobin RH, Futterweit W et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract 2015; 21(11): 1291–1300. doi: 10.4158/ EP15748. DSC.

16. Foretová L, Navrátilová M, Svoboda M et al. Doporučení pro sledování žen se vzácnějšími genetickými příčinami nádorů prsu a ovarií. Klin Onkol 2019; 32(Suppl 2): 2S6–2S13. doi: 10.14735/ amko2019S6.

17. Plevová P, Novotný J, Petráková K et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin Onkol 2009; 22(Suppl): S8–S11.

18. Foretová L, Macháčková E, Palácová M et al. Doporučení rozšíření indikačních kriterií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádorů prsu a ovarií. Klin Onkol 2016; 29(Suppl 1): S9–S13. doi: 10.14735/ amko2016S9.

19. Walsh T, Casadei S, Lee MK et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108(44): 18032–18037. doi: 10.1073/ pnas.1115052108.

20. Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction. Best Pract Res Clin Obstet Gynaecol 2017; 41: 31–48. doi: 10.1016/ j. bpobgyn.2016.10.017.

21. Schneider K, Zelley K, Nichols KE et al. Li- Fraumeni Syndrome. GeneReviews® 1999. 2019 [online]. Available from: https:/ / www.ncbi. nlm.nih.gov/ books/ NBK1311/ .

22. Win AK, Lindor NM, Young JP et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012; 104(18): 1363–1372.

23. Ketabi Z, Bartuma K, Bernstein I et al. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 2011; 121(3): 462–465. doi: 10.1016/ j.ygyno.2011.02.010.

24. McGarrity TJ, Amos ChI, Baker MJ. Peutz-Jeghers Syndrome. GeneReviews® 2001. 2021 [online]. Available from: https:/ / www.ncbi. nlm.nih.gov/ books/ NBK1266/ .

25. Neto N, Cunha TM. Do hereditary syndromerelated gynecologic cancers have any specific features? Insights Imaging 2015; 6(5): 545–552. doi: 10.1007/ s13244-015-0425-x.

26. Fujii K, Miyashita T. Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review. Pediatr Int 2014; 56(5): 667– 674. doi: 10.1111/ ped.12461.

27. Plevová P, Krutílková V, Puchmajerová A et al. Gorlinův syndrom. Klin Onkol 2009; 22(Suppl): S34–S35.

28. Aram S, Moghaddam NA. Bilateral ovarian fibroma associated with Gorlin syndrome. J Res Med Sci 2009; 14(1): 57–61.

29. Howell CG Jr, Rogers DA, Gable DS et al. Bilateral ovarian fibromas in children. J Pediatr Surg 1990; 25(6): 690–691. doi: 10.1016/ 0022-3468(90)90366-h.

30. Bennett C. PALB2 linked to increased risk for breast, ovarian, and pancreatic cancer. 2022 [online]. Available from: https:/ / www. cancertherapyadvisor.com/ home/ cancer-topics/ breast-cancer/ palb2-breast-ovarian-pancreatic- cancer-higher-risk-link/ .

31. PALB2 interest group. PALB2 mutation and cancer risks. 2022 [online]. Available from: https:/ / www.palb2.org/ about-the-palb2-gene/ palb2-mutation-and-cancer-risks/ .

32. Soukupová J, Lhotová K, Zemánková P et al. Přínos masivního paralelního sekvenování pro diagnostiku dědičných forem nádoru ovaria v České republice. Klin Onkol 2019; 32 (Suppl 2): 2S72–2S78. doi: 10.14735/ amko2019 S72.

33. Benerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013; 19(5): 961–968. doi: 10.1158/ 1078-0432. CCR-12-2243.

34. Plevová, P, Geržová H. Vzácné pediatrické ovariální tumory a jejich genetické příčiny. Klin Onkol 2019; 32(Suppl 2): 2S79–2S91. doi: 10.14735/ amko2019S79.

35. McCann-Crosby B, Mansouri R, Dietrich JE et al. State of the art review in gonadal dysgenesis: challenges in diagnosis and management. Int J Pediatr Endocrinol 2014; 2014(1): 4. doi: 10.1186/ 1687-9856-2014-4.

36. Škarpa P. Patologie a histopatologická klasifikace karcinomů ovaria. In: Fínek J, Zikán M et al (eds). Karcinom ovaria. 1st ed. Praha: Farmakon Press s.r.o. 2019: 14–21.

37. Šišovská I, Minář L, Felsinger M et al. Novinky ve FIGO stagingu karcinomu ovaria, tuby a peritonea. Ceska Gynekol 2017; 82(3): 230–236.

38. Ústav zdravotnických informací a statistiky ČR. Světový den boje s rakovinou vaječníků. 2021 [online].Available from: https:/ / www.uzis. cz/ index.php?pg=aktuality&aid=8493&fbclid=I wAR1wShGfYxs-bIm84xHqOFkU9ImFS9Mb2To N2XernKtOyU2gFLoiS3Sam_U.

39. Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent germ cell tumors in the United states, 1975 to 2006. Cancer 2010; 116(20): 4882–4891. doi: 10.1002/ cncr.25454.

40. Schultz KAP, Sencer SF, Messinger Y et al. Pediatric ovarian tumors: a review of 67 cases. Pediatr Blood Cancer 2005; 44(2): 167–173. doi: 10.1002/ pbc.20233.

41. Petráková K, PalácováM, Schneiderová M et al. Syndrom hereditárního prsu a ovarií. Klin Onkol 2016; 32(Suppl 1): S14–S21. doi: 10.14735/ amko216S14.